{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:17:23Z","timestamp":1783073843582,"version":"3.54.6"},"reference-count":23,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Non-muscle invasive bladder cancer (NMIBC) is characterized by high recurrence rates despite appropriate treatment and surveillance. Identifying inexpensive and readily available biomarkers capable of improving risk stratification remains an important clinical challenge. The platelet-to-lymphocyte ratio (PLR), a marker of systemic inflammation, has emerged as a potential prognostic indicator in several malignancies. This study aimed to evaluate the association between preoperative PLR, tumor recurrence, and recurrence-free survival (RFS) in NMIBC patients treated with intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) or thermochemotherapy. Methods: This retrospective study included 153 patients diagnosed with NMIBC between January 2020 and January 2024. All patients underwent transurethral resection of bladder tumor (TURBT) followed by intravesical BCG (n = 123) or thermochemotherapy (n = 30). Preoperative PLR was calculated from complete blood counts obtained before surgery. Receiver operating characteristic (ROC) analysis was used to determine the optimal PLR cut-off value. Recurrence-free survival was evaluated using Kaplan\u2013Meier survival analysis and Cox proportional hazards regression models. Results: During a mean follow-up period of approximately 19 months, recurrence was observed in 35.8% of patients treated with BCG and 30% of those treated with thermochemotherapy. ROC analysis demonstrated good discriminatory ability for recurrence prediction (AUC = 0.831, 95% CI: 0.761\u20130.901, p &lt; 0.001) and identified an optimal PLR threshold of 120. Patients with elevated PLR values demonstrated higher recurrence rates and shorter recurrence-free survival. Kaplan\u2013Meier analysis revealed a clear separation of survival curves according to PLR status. In multivariable Cox regression analysis, PLR &gt; 120 remained independently associated with recurrence-free survival in the BCG group (HR = 2.703, 95% CI: 1.118\u20136.534, p = 0.027), whereas only a borderline association was observed in the thermochemotherapy group (HR = 23.265, 95% CI: 0.952\u2013568.336, p = 0.054). Conclusions: Elevated preoperative PLR was associated with recurrence and recurrence-free survival in patients with NMIBC. The prognostic value of PLR appeared to be more pronounced in patients receiving intravesical BCG therapy. Given its low cost, accessibility, and ease of calculation, PLR may serve as a useful adjunctive biomarker for clinical risk stratification when used alongside established clinicopathological prognostic factors. Further prospective multicenter studies are required to validate these findings.<\/jats:p>","DOI":"10.3390\/jcm15135199","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:59:47Z","timestamp":1783065587000},"page":"5199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative Platelet-to-Lymphocyte Ratio as a Predictor of Recurrence and Recurrence-Free Survival in Non-Muscle-Invasive Bladder Cancer Across Different Intravesical Therapies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0687-5954","authenticated-orcid":false,"given":"Muhammet \u0130hsan","family":"\u00d6zt\u00fcrk","sequence":"first","affiliation":[{"name":"Alaca State Hospital, \u00c7orum 19600, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Ekici","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine, Hitit University, \u00c7orum 19040, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemil","family":"Ayd\u0131n","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine, Hitit University, \u00c7orum 19040, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Serdar","family":"\u00c7a\u011flayan","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine, Hitit University, \u00c7orum 19040, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fccahit","family":"Do\u011fan","sequence":"additional","affiliation":[{"name":"Meng\u00fccek Gazi Training and Research Hospital, Erzincan 24100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Murat","family":"Baykam","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine, Hitit University, \u00c7orum 19040, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: A Review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (Ta, T1, and Carcinoma In Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder Cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/curroncol31020079","article-title":"BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1007\/s00345-023-04332-z","article-title":"Efficacy of Hyperthermic Intravesical Chemotherapy (HIVEC) in Patients with Non-Muscle-Invasive Bladder Cancer after BCG Failure","volume":"41","author":"Pignot","year":"2023","journal-title":"World J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1007\/s11255-023-03924-3","article-title":"Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: A single-arm study","volume":"56","author":"Brisuda","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-Related Inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-Related Inflammation and Treatment Effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0146","article-title":"Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-analysis","volume":"23","author":"Templeton","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, X., Ni, X., and Tang, G. (2019). Prognostic Role of Platelet-to-Lymphocyte Ratio in Bladder Cancer: A Meta-analysis. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00757"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"FSO709","DOI":"10.2144\/fsoa-2021-0008","article-title":"Neutrophil Percentage-to-Albumin Ratio Predicts Mortality in Bladder Cancer Patients Treated with Radical Cystectomy","volume":"7","author":"Ferro","year":"2021","journal-title":"Future Sci. OA"},{"key":"ref_15","first-page":"191","article-title":"Prognostic Value of Systemic Inflammatory Response Biomarkers in Urothelial Carcinoma: A Systematic Review and Meta-analysis","volume":"40","author":"Mori","year":"2022","journal-title":"Urol. Oncol."},{"key":"ref_16","unstructured":"Chen, H., Wu, X., Wen, Z., Wang, Y., and Wang, H. (2022). Prognostic Significance of Preoperative Inflammatory Biomarkers in Non-Muscle-Invasive Bladder Cancer. BMC Urol., 22."},{"key":"ref_17","first-page":"1045","article-title":"Prognostic Impact of Platelet-to-Lymphocyte Ratio in Patients Receiving Intravesical BCG Therapy for Non-Muscle-Invasive Bladder Cancer","volume":"106","author":"Wu","year":"2022","journal-title":"Urol. Int."},{"key":"ref_18","first-page":"112","article-title":"Platelet-to-Lymphocyte Ratio and Outcomes in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis","volume":"43","author":"Hu","year":"2025","journal-title":"World J. Urol."},{"key":"ref_19","first-page":"79","article-title":"The Clinical Use of Inflammatory Markers in Urothelial Carcinoma","volume":"17","author":"Marchioni","year":"2016","journal-title":"Curr. Urol. Rep."},{"key":"ref_20","first-page":"1185347","article-title":"Prognostic Value of Platelet-to-Lymphocyte Ratio in Urothelial Carcinoma: Updated Meta-analysis","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What Is the Significance of Variant Histology in Urothelial Carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"\u015alusarczyk, A., Zapa\u0142a, P., Zapa\u0142a, \u0141., and Radziszewski, P. (2023). Impact of Smoking on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer. Cancers, 15.","DOI":"10.3390\/cancers15184660"},{"key":"ref_23","first-page":"731","article-title":"Artificial Intelligence and Biomarker-Based Prediction Models in Non-Muscle-Invasive Bladder Cancer","volume":"17","author":"Bardowska","year":"2025","journal-title":"Cancers"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:32:25Z","timestamp":1783071145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":23,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135199"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135199","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}